Strides Shasun’s wholly owned subsidiary Strides Pharma Global Pte Ltd has received final approval from the United States Food & Drug Administration (USFDA), for Ibuprofen tablets USP, 200 mg (OTC).

Ibuprofen is a generic version of Motrin IB tablets, 200 mg, of Johnson & Johnson Consumer, Inc. Ibuprofen is used for reliving pain from various conditions such as headache, dental pain, muscle aches, or arthritis and also to reduce fever and to relieve minor aches and pain due to the common cold or flu. Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID).

Further, the company stated, “The approval further strengthens Strides Ibuprofen franchise for the US markets that now comprises of 7 approved products addressing a combined Rx and OTC opportunity of $900 million as per IMS and IRi data.”

Read EquityPandit’s Technical Analysis of Nifty Pharma Outlook for The Week